BioArctic’s partner Eisai presented new data on the drug candidate Lecanemab back-up at the Clinical Trials on Alzheimer’s Disease conference (CTAD), November 4-7. The presentations included study design and initial screening results from the Phase 3 study AHEAD 3-45, the baseline characteristics of currently enrolled Alzheimer’s disease patients in the Phase 3 study Clarity AD, and an update on the effect of Lecanemab back-up on amyloid brain levels and the ARIA-E frequency for patients enrolled in the Phase 2b open label extension study.